Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

Inclusion Criteria: * Must have results from their initial diagnosis available at the time of screening to confirm all the following : 1. Diagnosis of multiple myeloma according to the diagnostic 2. Symptomatic de novo Multiple Myeloma * Be eligible for high-dose therapy with autologous stem cell transplantation * Autologous cell graft with a total number of CD 34 cells \> or = 5 X 106/kg before freezing Exclusion Criteria: * Progressive disease * Females participants pregnant or breast-feeding * A known infection by the human immunodeficiency virus * An active viral hepatitis B or C * Unstable angina or myocardial infarction within 4 months prior to inclusion, heart failure NYHA class III or IV angina, uncontrolled, history of severe coronary artery disease, an uncontrolled serious ventricular arrhythmia, a sick sinus syndrome, or electrocardiographic evidence of acute ischemia or conduction disturbances grade 3 unless the patient has a pacemaker * Uncontrolled hypertension or uncontrolled diabetes within 14 days before enrollment * A history of another malignancy. If cancer was diagnosed more than 10 years and considered as cured, an authorization may be requested on a case-by-case basis after discussion with the principal investigator * A significant neuropathy of grade 3-4 or grade 2 with pain in the 14 days prior to enrollment